Shehnaz K Hussain1, Solomon B Makgoeng, Matthew J Everly, Marc T Goodman, Otoniel Martínez-Maza, Lindsay M Morton, Christina A Clarke, Charles F Lynch, Jon Snyder, Ajay Israni, Bertram L Kasiske, Eric A Engels. 1. 1 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA. 3 Terasaki Foundation Laboratory, Los Angeles, CA. 4 Departments of Obstetrics and Gynecology and Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA. 5 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD. 6 Cancer Prevention Institute of California, Fremont, CA. 7 Division of Epidemiology, Department of Health Research and Policy and Medicine, Stanford University School of Medicine, Stanford, CA. 8 Department of Epidemiology, University of Iowa, Iowa City, IA. 9 Scientific Registry of Transplant Recipients and Minneapolis Medical Research Foundation, Minneapolis, Minneapolis, MN.
Abstract
BACKGROUND: Solid organ transplant recipients have heightened risk for diffuse large B cell lymphoma (DLBCL). The role of donor-recipient HLA mismatch and recipient HLA type on DLBCL risk are not well established. METHODS: We examined 172 231 kidney, heart, pancreas, and lung recipients transplanted in the United States between 1987 and 2010, including 902 with DLBCL. Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk in relation to HLA mismatch, types, and zygosity, adjusting for sex, age, race/ethnicity, year, organ, and transplant number. RESULTS: Compared with recipients who had 2 HLA-DR mismatches, those with zero or 1 mismatch had reduced DLBCL risk, (zero: IRR, 0.76, 95% confidence interval [95% CI], 0.61-0.95; one: IRR, 0.83; 95% CI, 0.69-1.00). In stratified analyses, recipients matched at either HLA-A, -B, or -DR had a significantly reduced risk of late-onset (>2 years after transplantation), but not early-onset DLBCL, and there was a trend for decreasing risk with decreasing mismatch across all 3 loci (P = 0.0003). Several individual recipient HLA-A, -B, -C, -DR, and -DQ antigens were also associated with DLBCL risk, including DR13 (IRR, 0.74; 95% CI, 0.57-0.93) and B38 (IRR, 1.48; 95% CI, 1.10-1.93), confirming prior findings that these 2 antigens are associated with risk of infection-associated cancers. CONCLUSIONS: In conclusion, variation in HLA is related to susceptibility to DLBCL, perhaps reflecting intensity of immunosuppression, control of Epstein-Barr virus infection among transplant recipients or chronic immune stimulation.
BACKGROUND: Solid organ transplant recipients have heightened risk for diffuse large B cell lymphoma (DLBCL). The role of donor-recipient HLA mismatch and recipient HLA type on DLBCL risk are not well established. METHODS: We examined 172 231 kidney, heart, pancreas, and lung recipients transplanted in the United States between 1987 and 2010, including 902 with DLBCL. Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk in relation to HLA mismatch, types, and zygosity, adjusting for sex, age, race/ethnicity, year, organ, and transplant number. RESULTS: Compared with recipients who had 2 HLA-DR mismatches, those with zero or 1 mismatch had reduced DLBCL risk, (zero: IRR, 0.76, 95% confidence interval [95% CI], 0.61-0.95; one: IRR, 0.83; 95% CI, 0.69-1.00). In stratified analyses, recipients matched at either HLA-A, -B, or -DR had a significantly reduced risk of late-onset (>2 years after transplantation), but not early-onset DLBCL, and there was a trend for decreasing risk with decreasing mismatch across all 3 loci (P = 0.0003). Several individual recipient HLA-A, -B, -C, -DR, and -DQ antigens were also associated with DLBCL risk, including DR13 (IRR, 0.74; 95% CI, 0.57-0.93) and B38 (IRR, 1.48; 95% CI, 1.10-1.93), confirming prior findings that these 2 antigens are associated with risk of infection-associated cancers. CONCLUSIONS: In conclusion, variation in HLA is related to susceptibility to DLBCL, perhaps reflecting intensity of immunosuppression, control of Epstein-Barr virus infection among transplant recipients or chronic immune stimulation.
Authors: Manuel Muro; María R López-Álvarez; Jose A Campillo; Luis Marin; María R Moya-Quiles; Jose M Bolarín; Carmen Botella; Gema Salgado; Pedro Martínez; Francisco Sánchez-Bueno; Ruth López-Hernández; Francisco Boix; Alexandre Bosch; Helios Martínez; Jesús M de la Peña-Moral; Noelia Pérez; Ricardo Robles; Ana M García-Alonso; Alfredo Minguela; Manuel Miras; María R Alvarez-López Journal: Transpl Immunol Date: 2011-11-23 Impact factor: 1.708
Authors: Sophia S Wang; Idan Menashe; James R Cerhan; Wendy Cozen; Richard K Severson; Scott Davis; Amy Hutchinson; Nathaniel Rothman; Stephen J Chanock; Leslie Bernstein; Patricia Hartge; Lindsay M Morton Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-12-10 Impact factor: 4.254
Authors: M Carrington; G W Nelson; M P Martin; T Kissner; D Vlahov; J J Goedert; R Kaslow; S Buchbinder; K Hoots; S J O'Brien Journal: Science Date: 1999-03-12 Impact factor: 47.728
Authors: M Subklewe; A Chahroudi; K Bickham; M Larsson; M G Kurilla; N Bhardwaj; R M Steinman Journal: Eur J Immunol Date: 1999-12 Impact factor: 5.532
Authors: Margaret M Madeleine; Lisa G Johnson; Anajane G Smith; John A Hansen; Brenda B Nisperos; Sue Li; Lue-Ping Zhao; Janet R Daling; Stephen M Schwartz; Denise A Galloway Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Stephen A Wheless; Margaret L Gulley; Nancy Raab-Traub; Patrick McNeillie; Isabel P Neuringer; Hubert J Ford; Robert M Aris Journal: Am J Respir Crit Care Med Date: 2008-08-28 Impact factor: 21.405
Authors: Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin Journal: JAMA Date: 2011-11-02 Impact factor: 157.335
Authors: Eric A Engels; Linda W Jennings; Matthew J Everly; Ola Landgren; Kazunori Murata; Elizabeth L Yanik; Ruth M Pfeiffer; Nicholas Onaca; Goran B Klintmalm Journal: Transplant Direct Date: 2018-05-15
Authors: Ranya Abdulovski; Dina L Møller; Andreas D Knudsen; Søren S Sørensen; Allan Rasmussen; Susanne D Nielsen; Neval E Wareham Journal: Eur J Haematol Date: 2022-07-14 Impact factor: 3.674